AnaptysBio is no longer a clinical-stage immunology biotech. On April 20, 2026, Anaptys completed the spin-off of its biopharma operations into First Tracks Biotherapeutics (Nasdaq: TRAX), and the company that remains is a focused royalty-management business sitting on two distinct cash-flow streams. The first quarter of 2026 was the last to carry the legacy biopharma expense base; the second quarter, due mid-November, will reclassify First Tracks as discontinued operations, restructure the income statement around the Jemperli royalty and the Vanda imsidolimab PDUFA, and - in management's framing - produce an EBIT margin "greater than 95%" on a stripped-down cost base. The Q1 2026 print was the most confusing quarter the company will ever report, and it was also the quarter that finally revealed the new shape of the business.
Two numbers tell the bull story. The first is the Jemperli royalty stream, which is now contractually trapped under a non-recourse Sagard financing that will unwind in 2027; the second is the Vanda imsidolimab PDUFA on December 12, 2026 for generalized pustular psoriasis, a market with no approved biologic and a 10% royalty attached. The bear counter is that Anaptys carries a $263.7M non-recourse Sagard liability on the balance sheet, owes $20.9M of non-cash interest against it every quarter, and reports from a base of stockholders' equity of just $12.7M - meaning the stock is a bet on cash flow from two molecules, not on book value. At $56.98 on August 12, 2026, the company carries a roughly $1.65B market cap against $286.5M of cash and zero traditional debt, for an enterprise value near $1.37B; the stock is up roughly 5x from a year ago on the spin-off announcement, and has retraced roughly 21% from its 52-week high set in early May.
A catalyst-loaded, capital-light royalty play, priced for execution. Anaptys will trade on three named dates over the next six months: the Q2 2026 print in November (the first "clean" pro-forma quarter), the Vanda PDUFA on December 12, 2026, and the Sagard non-recourse paydown that management expects to be complete by the end of Q2 2027. The thesis holds together or it doesn't on those three.